Investigational balloon gets reimbursement
This article was originally published in Clinica
Medicare patients participating in the Barath cutting balloon trial will receive reimbursement, following investigational device classification by the US FDA. The angioplasty balloon, which is manufactured by Interventional Technologies (US), has been classified as a category B investigational device, ie. a Class III device with technological advances compared to a PMA-approved device. The cutting balloon trial includes 1,250 patients at 30 centres worldwide.
You may also be interested in...
The companies think they can build out the indications for zuranalone and SAGE-324 faster and more broadly and commercialize the drugs more effectively as partners.
The guidance document allows manufacturers to promote their dry-heat systems for mask bioburden reduction if they meet certain standards.
The US Medicare agency is letting ambulatory surgical centers and patient homes be reimbursed as in-patient hospitals for patient care purposes during the pandemic.